| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.9M | — | -9.5% |
| R&D Expense | $19.9M | — | -31.3% |
| SG&A Expense | $9.9M | — | -0.6% |
| Operating Income | -$25.2M | — | +11.3% |
| Pre-tax Income | -$33.0M | — | +14.2% |
| Income Tax | $0 | — | -100.0% |
| Net Income | -$33.0M | — | +14.6% |
| EPS (Basic) | -$0.21 | — | +41.7% |
| EPS (Diluted) | -$0.21 | — | +41.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $231.0M | -11.6% | +18.6% |
| Accounts Receivable | $31.0M | +6.6% | -2.3% |
| Inventory | $4.8M | +14.1% | -72.6% |
| Current Assets | $276.8M | -9.7% | +7.3% |
| Total Assets | $291.5M | -9.8% | +7.0% |
| Current Liabilities | $67.6M | -3.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$29.7M | — | +47.3% |
| Capital Expenditures | $32K | — | -87.9% |
| Investing Cash Flow | -$32K | — | +87.9% |
| Financing Cash Flow | -$583K | — | -315.1% |
| Free Cash Flow | -$29.7M | — | +47.5% |
| +17.0% |
| Total Liabilities | $507.9M | -0.2% | -0.6% |
| Stockholders' Equity | -$216.4M | -16.4% | +9.2% |